By Fineline Cube 
China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) announced last week that it has entered into a co-promotion agreement with Kowa Pharmaceuticals (China) Co., Ltd., a subsidiary of Japan’s Kowa Company Ltd. The collaboration centers on Parmodia (pemafibrate), with Gloria Pharma taking charge of promotion activities in the designated area. In return, Kowa Pharma will provide service fees and promotional support.
Parmodia’s Approval and Indication
Parmodia, recognized as the world’s first highly selective peroxisome proliferator-activated receptor alpha (PPARα) agonist, received approval in China in April 2025. It is indicated for the treatment of non-familial hypertriglyceridemia in adult patients to reduce triglyceride (TG) levels, in addition to dietary management.-Fineline Info & Tech